Ercros Valuation
Is CRS1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CRS1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CRS1 (€3.45) is trading below our estimate of fair value (€4.08)
Significantly Below Fair Value: CRS1 is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CRS1?
Key metric: As CRS1 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is CRS1's PE Ratio? | |
|---|---|
| PE Ratio | 22.9x |
| Earnings | €14.10m |
| Market Cap | €322.31m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.7x |
| Enterprise Value/EBITDA | 91.1x |
| PEG Ratio | 0.5x |
Price to Earnings Ratio vs Peers
How does CRS1's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 12.9x | ||
SIM0 SIMONA | 11.1x | n/a | €348.0m |
FPE3 Fuchs | 18.6x | 8.7% | €4.9b |
UZU Uzin Utz | 10.5x | 2.1% | €251.2m |
ACT AlzChem Group | 11.5x | 12.8% | €578.0m |
CRS1 Ercros | 22.9x | 48.5% | €322.3m |
Price-To-Earnings vs Peers: CRS1 is expensive based on its Price-To-Earnings Ratio (22.9x) compared to the peer average (12.9x).
Price to Earnings Ratio vs Industry
How does CRS1's PE Ratio compare vs other companies in the European Chemicals Industry?
| 2 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 2 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: CRS1 is expensive based on its Price-To-Earnings Ratio (22.9x) compared to the European Chemicals industry average (16.8x).
Price to Earnings Ratio vs Fair Ratio
What is CRS1's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 22.9x |
| Fair PE Ratio | 24.9x |
Price-To-Earnings vs Fair Ratio: CRS1 is good value based on its Price-To-Earnings Ratio (22.9x) compared to the estimated Fair Price-To-Earnings Ratio (24.9x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Compañía de Minas BuenaventuraA
US$3.1b
Engages in the exploration, development, construction, and operation of mineral processing business.
MBU
US$11.70
7D
0%
1Y
35.3%
Mitsubishi Chemical Group
JP¥1.1t
Provides performance products, chemicals, industrial gases, health care products, and other products in Japan and internationally.
M3C
JP¥4.80
7D
-4.0%
1Y
-17.0%
Cabka
€59.3m
Manufactures and sells pallets and large containers made from recycled plastic in Europe, North America, and internationally.
7GW
€2.34
7D
-12.7%
1Y
-61.8%